Release details

2018-02-08 18:00 CET
  • Print
  • Share Share
en fr



Louvain-la-Neuve, Belgium, February 08, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notifications received on February 06, 2018.

Reason for the notification Upwards crossing followed by a downwards crossing of the 3% threshold further to the acquisition and disposal of shares -and thus voting rights- held as loan collateral
Persons subject to the notification requirement IBA SA, issuer
Persons that dispose of voting rights Norges Bank
Transaction date 02/02/2018   05/02/2018
Threshold that is crossed (in %) 3%
Upwards crossing further to the acquisition of voting rights
Downwards crossing further to the disposal of voting rights
Denominator 29 962 246   29 962 246
Voting rights (number) 899 545   859 382
Voting rights (%) 3,00%   2,87%
Chain of control Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway's foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

For further information, please contact:


Stephanie Bauwin
Legal Counsel
+32 10 203 924